How Oral Retatrutide in DROP Delivers Up to 24% Weight Loss – Clinical Updates and Real Results 2025
Retatrutide: A Triple‑Agonist for Obesity and Metabolic Diseases Introduction Retatrutide (LY3437943; Eli Lilly) is a novel investigational agent that simultaneously activates three incretin‑related receptors—the glucose‑dependent insulinotropic polypeptide (GIP), glucagon‑like peptide‑1 (GLP‑1), and glucagon receptors. This “triple agonist” approach aims to combine potent glucose control and profound weight‑loss benefits while addressing metabolic dysfunction beyond the capabilities of current single or dual incretin mimetics (e.g., semaglutide or tirzepatide). Mechanism of Action Retatrutide binds and activates GIP, GLP‑1, and glucagon receptors with balanced agonism in vitro. GLP‑1R stimulation: enhances glucose‑dependent insulin secretion, slows gastric emptying, and reduces appetite. GIPR activation: synergizes Beta‑cell function and amplifies postprandial insulin and increases energy expenditure and fatty acid oxidation, offsetting the potential hyperglycemia of pure glucag...